Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a …
B François, CE Luyt, A Dugard, M Wolff… - Critical care …, 2012 - journals.lww.com
Objective: The type III secretion system is an important Pseudomonas aeruginosa-virulence
determinant in animal models of infection and in humans. Antibody-mediated inhibition of
the PcrV protein, an essential component of this system, might abrogate the Pseudomonas
aeruginosa ability to damage epithelial cells, neutrophils, and macrophages, thereby limiting
its pathogenicity. The objective of the trial was to determine the safety, pharmacokinetics,
and ability to prevent Pseudomonas aeruginosa ventilator–associated pneumonia of KB001 …
determinant in animal models of infection and in humans. Antibody-mediated inhibition of
the PcrV protein, an essential component of this system, might abrogate the Pseudomonas
aeruginosa ability to damage epithelial cells, neutrophils, and macrophages, thereby limiting
its pathogenicity. The objective of the trial was to determine the safety, pharmacokinetics,
and ability to prevent Pseudomonas aeruginosa ventilator–associated pneumonia of KB001 …
